TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2025. Filed Feb 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 3, 2026
TEVA$42.97+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance sheets
| December 31,2025 | December 31,2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $3,556 | $3,300 |
| Accounts receivables, net of allowance for credit losses of $81 million and $78 million as of December 31, 2025 and December 31, 2024, respectively | 3,709 | 3,059 |
| Inventories | 3,179 | 3,007 |
| Prepaid expenses | 1,122 | 1,006 |
| Other current assets | 539 | 409 |
| Assets held for sale | 1,842 | 1,771 |
| Total current assets | 13,946 | 12,552 |
| Deferred income taxes | 2,191 | 1,799 |
| Other non-current assets | 405 | 462 |
| Property, plant and equipment, net | 4,080 | 4,581 |
| Operating lease right-of-use assets | 345 | 367 |
| Identifiable intangible assets, net | 3,781 | 4,418 |
| Goodwill | 16,000 | 15,147 |
| Total assets | $40,748 | $39,326 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Short-term debt | $1,820 | $1,781 |
| Sales reserves and allowances | 4,143 | 3,678 |
| Accounts payables | 2,531 | 2,203 |
| Employee-related obligations | 739 | 624 |
| Accrued expenses | 2,687 | 2,792 |
| Other current liabilities | 1,182 | 1,020 |
| Liabilities held for sale | 354 | 698 |
| Total current liabilities | 13,456 | 12,796 |
| Long-term liabilities: | ||
| Deferred income taxes | 296 | 483 |
| Other taxes and long-term liabilities | 3,808 | 4,028 |
| Senior notes and loans | 14,986 | 16,002 |
| Operating lease liabilities | 288 | 296 |
| Total long-term liabilities | 19,379 | 20,809 |
| Total liabilities | 32,834 | 33,606 |
| Redeemable non-controlling interests | — | 340 |
| Equity: | ||
| Teva shareholders’ equity: | ||
| Ordinary shares of NIS 0.10 par value per share; December 31, 2025 and December 31, 2024: authorized 2,495 million shares; issued 1,257 million shares and 1,240 million shares, respectively | 58 | 58 |
| Additional paid-in capital | 28,133 | 27,764 |
| Accumulated deficit | (13,762) | (15,173) |
| Accumulated other comprehensive loss | (2,391) | (3,148) |
| Treasury shares as of December 31, 2025 and December 31, 2024: 107 million ordinary shares | (4,128) | (4,128) |
| 7,910 | 5,373 | |
| Non-controlling interests | 4 | 7 |
| Total equity | 7,914 | 5,380 |
| Total liabilities, redeemable non-controlling interests and equity | $40,748 | $39,326 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.